Enanta Pharmaceuticals Reports Mixed Q3 2026 Results Amid RSV and Immunology Pipeline Progress
Event summary
- Enanta reported Q3 2026 revenue of $14.4M, down from $18.3M in Q3 2025 due to lower AbbVie HCV sales.
- Net loss narrowed slightly to $19.5M (Q3 2025: $18.3M) as R&D expenses decreased by $5.1M.
- Zelicapavir Phase 2b trial in pediatric RSV patients began dosing, with topline data expected in 2027.
- Registrational Phase 2b/3 trial for zelicapavir in high-risk adults with RSV to initiate in Q4 2026.
- EDP-978 Phase 1 trial topline data expected in Q4 2026, with EPS-3903 IND filing targeted for H2 2026.
The big picture
Enanta is positioning itself as a leader in RSV antiviral treatments and immunology therapies. The company's strategic focus on advancing zelicapavir through registrational trials and developing novel immunology candidates aims to address significant unmet medical needs. However, its financial performance remains challenged by declining royalty revenue from AbbVie's HCV products and ongoing R&D investments.
What we're watching
- RSV Market Potential
- Whether zelicapavir can capture significant market share as the first approved antiviral therapy for RSV, addressing a substantial unmet need in both pediatric and high-risk adult populations.
- Immunology Pipeline Progress
- The pace at which Enanta advances its immunology programs, particularly EDP-978 and EPS-3903, toward commercialization and their potential to diversify revenue streams beyond RSV.
- Royalty Revenue Sustainability
- How AbbVie's HCV sales trends will impact Enanta's royalty revenue, particularly given the ongoing debt liability payments to OMERS through 2032.
Related topics